Ipsen | Balance Sheet

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
131
186
233
432
258
345
Total Accounts Receivable
320
348
447
473
547
583
Inventories
122
106
107
113
167
199
Other Current Assets
30
32
22
32
45
59
Total Current Assets
602
672
810
1,050
1,016
1,186
Net Property, Plant & Equipment
288
310
349
379
419
475
Total Investments and Advances
10
34
42
37
171
174
Intangible Assets
456
485
505
737
1,319
1,408
Other Assets
8
8
15
7
3
4
Total Assets
1,565
1,713
1,938
2,424
3,070
3,377
ST Debt & Current Portion LT Debt
13
14
19
43
293
Accounts Payable
155
180
195
242
319
Income Tax Payable
6
4
12
4
2
Other Current Liabilities
203
212
236
272
328
Total Current Liabilities
376
410
462
561
942
Long-Term Debt
12
12
21
297
298
Provision for Risks & Charges
91
102
83
80
101
Deferred Taxes
196
199
195
199
121
Other Liabilities
106
116
125
108
174
Total Liabilities
592
645
712
1,061
1,536
Common Equity (Total)
972
1,065
1,223
1,359
1,523
Total Shareholders' Equity
972
1,065
1,223
1,359
1,523
Total Equity
974
1,068
1,226
1,362
1,534
Liabilities & Shareholders' Equity
1,565
1,713
1,938
2,424
3,070
Accumulated Minority Interest
2
3
3
3
11

About Ipsen

View Profile
Address
65, quai Georges Gorse
Boulogne-Billancourt Ile-de-France 92650
France
Employees -
Website http://www.ipsen.com
Updated 07/08/2019
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin.